Pondimin Side Effects
Generic name: fenfluramine
Medically reviewed by Drugs.com. Last updated on Jul 1, 2024.
Note: This document provides detailed information about Pondimin Side Effects associated with fenfluramine. Some dosage forms listed on this page may not apply specifically to the brand name Pondimin.
Applies to fenfluramine: oral solution.
Important warnings
This medicine can cause some serious health issues
REMS:
FDA approved a REMS for fenfluramine to ensure that the benefits outweigh the risks.
The REMS may apply to one or more preparations of fenfluramine and consists of the following: elements to assure safe use and implementation system.
See the FDA REMS page ([Web]).
Side effects include:
Decreased appetite, somnolence, sedation, lethargy, diarrhea, constipation, abnormal echocardiogram, fatigue, malaise, asthenia, ataxia, balance disorder, gait disturbance, increased BP, drooling, salivary hypersecretion, pyrexia, upper respiratory tract infection, vomiting, decreased weight, falls, status epilepticus.
For healthcare professionals
Applies to fenfluramine: oral solution, oral tablet.
General adverse events
The more commonly reported adverse effects have included decreased appetite and weight, somnolence, sedation, lethargy, diarrhea, constipation, increased blood pressure, gait disturbances, balance disorder, pyrexia, asthenia, vomiting, fall, and status epilepticus.[Ref]
Cardiovascular
- Very common (10% or more): Abnormal echocardiogram (up to 23%), increased blood pressure (up to 13%)
- Common (1% to 10%): Increased heart rate[Ref]
Abnormal echocardiogram included trace and mild mitral regurgitation, and trace aortic regurgitation, which are considered physiologic. Valvular heart disease and pulmonary arterial hypertension were evaluated in the clinical studies via echocardiography for up to 3 years in duration and no patient developed findings consistent with either condition. During the open-label extension study, trace mitral regurgitation and trace aortic regurgitation were reported in 14% and 0.4%, respectively. Trace and mild mitral regurgitation, and trace aortic regurgitation are
considered physiologic in the absence of structural valve abnormalities.[Ref]
Nervous system
- Very common (10% or more): Somnolence, sedation, and lethargy (26%)
- Common (1% to 10%): Ataxia, balance disorder, gait disturbance, hypotonia, falls, headache, status epilepticus, stereotypy, tremor[Ref]
Metabolic
- Very common (10% or more): Decreased appetite (up to 49%), decreased weight (up to 13%)
- Common (1% to 10%): Dehydration, decreased blood glucose[Ref]
This drug decreases appetite and causes dose-related weight loss. In clinical studies, decreased appetite and weight were reported in 37% and 9%, respectively (placebo=8% and 1%). Weight loss of 7% or greater from baseline was reported in 19% of patients treated with this drug compared to 2% of patients on placebo.[Ref]
Psychiatric
- Common (1% to 10%): Abnormal behavior, insomnia, irritability, negativism
- Postmarketing reports: Aggression[Ref]
Genitourinary
- Common (1% to 10%): Urinary incontinence, enuresis, urinary tract infection[Ref]
Respiratory
- Very common (10% or more): Upper respiratory infections (up to 21%)
- Common (1% to 10%): Bronchitis, croup, rhinitis, laryngitis[Ref]
Other
- Very common (10% or more): Fatigue, malaise, and asthenia (up to 30%), pyrexia (up to 21%)
- Common (1% to 10%): Chills, decreased activity, contusion, ear infection[Ref]
Dermatologic
Endocrine
- Common (1% to 10%): Blood prolactin increase[Ref]
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 31%), drooling and/or salivary hypersecretion (up to 13%)
- Common (1% to 10%): Constipation, gastroenteritis, vomiting[Ref]
Musculoskeletal
- Common (1% to 10%): Hypotonia[Ref]
Ocular
See also:
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Zepbound
Zepbound (tirzepatide) is an FDA-approved weekly injection for weight loss and obstructive sleep ...
Victoza
Victoza helps control blood sugar levels and reduce the risk of serious heart problems in people ...
Saxenda
Saxenda (liraglutide) injection is used for weight loss in obese or overweight patients. Includes ...
Alli
alli blocks the absorption of some of the fat that you eat and is used to treat obesity. Learn ...
Tirzepatide
Tirzepatide is a once-weekly injection used for weight loss, sleep apnea, and type 2 diabetes ...
Phentermine
Phentermine is an appetite suppressant used together with diet and exercise to treat obesity. Learn ...
References
1. (2020) "Product Information. Fintepla (fenfluramine)." Zogenix, Inc
2. (2023) "Product Information. Fintepla (fenfluramine)." UCB Pharma Ltd, SUPPL-13
3. (2024) "Product Information. Velsipity (etrasimod)." Pfizer Australia Pty Ltd, pfpvelst11024
Frequently asked questions
- How long does it take Fintepla to work?
- Is Fintepla a controlled substance?
- What type of epilepsy is Diacomit used to treat?
- How is Fintepla injected/administered?
More about Pondimin (fenfluramine)
- Check interactions
- Compare alternatives
- Drug images
- Dosage information
- During pregnancy
- Drug class: anorexiants
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Pondimin side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.